The stock has a 36-month beta value of 0.69. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for HOOK is 7.19M, and at present, short sellers hold a 0.42% of that float. On December 27, 2024, the average trading volume of HOOK was 53.43K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
HOOK) stock’s latest price update
The stock price of Hookipa Pharma Inc (NASDAQ: HOOK) has dropped by -2.37 compared to previous close of 1.89. Despite this, the company has seen a fall of -7.50% in its stock price over the last five trading days. globenewswire.com reported 2024-11-11 that Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety
HOOK’s Market Performance
Hookipa Pharma Inc (HOOK) has experienced a -7.50% fall in stock performance for the past week, with a -19.04% drop in the past month, and a -55.85% drop in the past quarter. The volatility ratio for the week is 9.09%, and the volatility levels for the past 30 days are at 9.14% for HOOK. The simple moving average for the past 20 days is -18.22% for HOOK’s stock, with a -66.84% simple moving average for the past 200 days.
Analysts’ Opinion of HOOK
Many brokerage firms have already submitted their reports for HOOK stocks, with RBC Capital Mkts repeating the rating for HOOK by listing it as a “Sector Perform.” The predicted price for HOOK in the upcoming period, according to RBC Capital Mkts is $2 based on the research report published on December 20, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see HOOK reach a price target of $48, previously predicting the price at $50. The rating they have provided for HOOK stocks is “Outperform” according to the report published on November 15th, 2024.
BofA Securities gave a rating of “Underperform” to HOOK, setting the target price at $0.50 in the report published on December 02nd of the previous year.
HOOK Trading at -37.94% from the 50-Day Moving Average
After a stumble in the market that brought HOOK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.38% of loss for the given period.
Volatility was left at 9.14%, however, over the last 30 days, the volatility rate increased by 9.09%, as shares sank -20.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.32% lower at present.
During the last 5 trading sessions, HOOK fell by -7.50%, which changed the moving average for the period of 200-days by -74.83% in comparison to the 20-day moving average, which settled at $2.2622. In addition, Hookipa Pharma Inc saw -77.16% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for HOOK
Current profitability levels for the company are sitting at:
- -0.94 for the present operating margin
- 0.96 for the gross margin
The net margin for Hookipa Pharma Inc stands at -0.87. The total capital return value is set at -0.58. Equity return is now at value -51.99, with -31.69 for asset returns.
Currently, EBITDA for the company is -77.34 million with net debt to EBITDA at 1.36. When we switch over and look at the enterprise to sales, we see a ratio of -0.78. The receivables turnover for the company is 2.0for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.26.
Conclusion
To sum up, Hookipa Pharma Inc (HOOK) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
